181 related articles for article (PubMed ID: 19400950)
1. Activation of p53-regulated pro-apoptotic signaling pathways in PrP-mediated myopathy.
Liang J; Parchaliuk D; Medina S; Sorensen G; Landry L; Huang S; Wang M; Kong Q; Booth SA
BMC Genomics; 2009 Apr; 10():201. PubMed ID: 19400950
[TBL] [Abstract][Full Text] [Related]
2. Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice.
Huang S; Liang J; Zheng M; Li X; Wang M; Wang P; Vanegas D; Wu D; Chakraborty B; Hays AP; Chen K; Chen SG; Booth S; Cohen M; Gambetti P; Kong Q
Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6800-5. PubMed ID: 17420473
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
4. The cellular prion protein (PrPC) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation.
Kim BH; Lee HG; Choi JK; Kim JI; Choi EK; Carp RI; Kim YS
Brain Res Mol Brain Res; 2004 Apr; 124(1):40-50. PubMed ID: 15093684
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis gene profiling reveals spatio-temporal regulated expression of the p53/Mdm2 pathway during lens development.
Geatrell JC; Gan PM; Mansergh FC; Kisiswa L; Jarrin M; Williams LA; Evans MJ; Boulton ME; Wride MA
Exp Eye Res; 2009 Jun; 88(6):1137-51. PubMed ID: 19450442
[TBL] [Abstract][Full Text] [Related]
6. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
7. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of p53(+/-) knockout and wild-type mice following diethylstilbestrol administration.
Salleh MN; Ismail P; Abdullah AS; Taufiq-Yap YH
IUBMB Life; 2004 Jul; 56(7):409-16. PubMed ID: 15545218
[TBL] [Abstract][Full Text] [Related]
9. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
10. Cellular prion protein overexpression disturbs cellular homeostasis in SH-SY5Y neuroblastoma cells but does not alter p53 expression: a proteomic study.
Weiss E; Ramljak S; Asif AR; Ciesielczyk B; Schmitz M; Gawinecka J; Schulz-Schaeffer W; Behrens C; Zerr I
Neuroscience; 2010 Sep; 169(4):1640-50. PubMed ID: 20547212
[TBL] [Abstract][Full Text] [Related]
11. The P53 pathway: what questions remain to be explored?
Levine AJ; Hu W; Feng Z
Cell Death Differ; 2006 Jun; 13(6):1027-36. PubMed ID: 16557269
[TBL] [Abstract][Full Text] [Related]
12. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
13. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like 6 is induced by muscle injury and functions as a regenerative factor.
Zeng L; Akasaki Y; Sato K; Ouchi N; Izumiya Y; Walsh K
J Biol Chem; 2010 Nov; 285(46):36060-9. PubMed ID: 20807758
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns of cell cycle proteins in the livers of rats treated with hepatocarcinogens for 28 days.
Yafune A; Taniai E; Morita R; Nakane F; Suzuki K; Mitsumori K; Shibutani M
Arch Toxicol; 2013 Jun; 87(6):1141-53. PubMed ID: 23411599
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.
Fujioka S; Schmidt C; Sclabas GM; Li Z; Pelicano H; Peng B; Yao A; Niu J; Zhang W; Evans DB; Abbruzzese JL; Huang P; Chiao PJ
J Biol Chem; 2004 Jun; 279(26):27549-59. PubMed ID: 15102862
[TBL] [Abstract][Full Text] [Related]
18. Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response.
Li Z; Niu J; Uwagawa T; Peng B; Chiao PJ
J Biol Chem; 2005 Apr; 280(17):16843-50. PubMed ID: 15671037
[TBL] [Abstract][Full Text] [Related]
19. Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation.
Chiesa R; Pestronk A; Schmidt RE; Tourtellotte WG; Ghetti B; Piccardo P; Harris DA
Neurobiol Dis; 2001 Apr; 8(2):279-88. PubMed ID: 11300723
[TBL] [Abstract][Full Text] [Related]
20. Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis.
Sunyach C; Checler F
J Neurochem; 2005 Mar; 92(6):1399-407. PubMed ID: 15748158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
